OphthaliX announces
the appointment of Prof. Roger Kornberg as a Director
Carson City, Nevada, February 6, 2012 – OpththaliX Inc. (OTCBB: OPLI) is pleased to announce
the appointment of Professor Roger D. Kornberg to the Company’s Board of
Directors.
Roger Kornberg is Winzer
Professor in Medicine in the Department of Structural Biology at Stanford
University. He moved to his present position in 1978, where his research has
focused on the mechanism and regulation of eukaryotic gene transcription. In 2006,
Professor Kornberg was awarded the Nobel Prize in Chemistry in recognition for
his studies.
Prof. Kornberg was elected to the National
Academy of Sciences in 1993. He has received many awards, including the 2001
Welch prize, highest award in chemistry in the United States, the 2002 Leopold
Mayer Prize and the highest award in biomedical sciences of the French Academy
of Sciences.
He is a recipient of honorary degrees from
universities in Europe and Israel, including the Hebrew University, where he is
a visiting professor.
Prof. Kornberg is also serving as a director
of Teva Pharmaceuticals Industries Ltd. (NASDAQ:
TEVA) and Protalix BioTherapeutics
Inc. (AMEX: PLX).
Prof. Pnina Fishman, interim CEO and Chairman
of Ophthalix commented: "we are very pleased that Prof. Kornberg has
agreed to join our Board. His outstanding scientific achievements
and his experience serving on boards of leading
pharmaceutical and biotechnology companies will be extremely valuable as we
progress with our advanced clinical development programs".
About OphthaliX Inc.
OphthaliX Inc. is an advanced clinical-stage biopharmaceutical company
focused on developing therapeutic products for the treatment of ophthalmic
disorders. OphthaliX's product candidate, CF101, is
being developed to treat three ophthalmic indications: dry eye syndrome;
glaucoma and uveitis.
About
Can-Fite BioPharma Ltd
Can-Fite BioPharma Ltd is a public company, trading on the Tel Aviv Stock Exchange (TASE: CFIB). Can-Fite was founded in 2000 by Prof Pnina Fishman, researcher in the Rabin Medical Center, and Dr. Ilan Cohen, patent attorney and senior partner at Reinhold Cohen Patent Attorneys, on the basis of Prof Fishman’s scientific findings, and is focused on the development of small molecule drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. Can-Fite’s lead drug, CF101, is in advanced clinical development for the treatment of autoimmune, inflammatory and ophthalmic diseases. Can-Fite's second drug, CF102, is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience which includes over 700 patients who have participated in clinical trials conducted by it.
Contact:
Pnina Fishman, Interim Chief Executive Officer
Tel: +972-3-9241114
Email: pnina@ophthalix.com
This release contains forward-looking statements regarding Denali
Concrete Management, Inc.’s future plans and expected performance based on
assumptions the Company believes to be reasonable. A number of risks and
uncertainties could cause actual results to differ materially from these
statements, including, without limitation, the success rate of business
development efforts and the timeliness of development activities, and other
risk factors described from time to time in the Company’s reports filed with
the SEC. In addition, the Company operates in an industry sector where
securities values are highly volatile and may be influenced by economic and
other factors beyond the Company’s control. Denali Concrete Management, Inc.
undertakes no obligation to publicly update these forward-looking statements,
whether as a result of new information, future events or otherwise. The securities issued in the above
transaction have not been and will not be registered under the Act and may not
be offered or sold in the United States absent registration or an applicable
exemption from registration requirements.